V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody

Antigen: V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Synonyms: BRAF1, RAFB1, B-RAF1, FLJ95109, MGC126806, MGC138284, RMIL, C-RMIL, B-Raf, braf1, rafb1, b-raf1, BRAF

Clonality: Monoclonal (1H12)

Host: Mouse

Reactivity: Human, Mouse (Murine)

Application: ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)

Catalog no.: ABIN968991

Additional Information

Alternative name: BRAF

Gene ID: 673

Immunogen: Purified recombinant fragment of human BRAF expressed in E. Coli.

Format: Liquid

Isotype: IgG1

Clone: 1H12

Description: BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1. RAFB1. B-RAF1. FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.
Synonyms: BRAF1, RAFB1, B-RAF1, FLJ95109

Molecular Weight: 87kDa

Application Details

Application Notes: Western Blotting: 1/500 - 1/2000.
Immunohistochemistry: 1/200 - 1/1000.
Immunofluorescence: 1/200 - 1/1000.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test.

Purification: Ascites

Buffer: Ascitic fluid containing 0.03% sodium azide.

Preservative: 0.03% sodium azide

Storage: Store at 4℃, for long term storage, store at -20℃.

Restrictions: For Research Use only

Publications

Product: Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas et al.: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, 2006 (PubMed).

Di Nicolantonio, Martini, Molinari et al.: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, 2008 (PubMed).